iTeos Therapeutics ITOS 深 沪
等待开盘 12-20 09:30:00 美东时间
10.15
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 10.15
- 总市值 3.88亿
- 52周最高 17.63
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.80
- 委 比 0.00%
- 总股本 3827.38万
- 历史最高 52.43
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.80
- 每 手 1
- 风险率 1.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多【行业研究】创新药企业的信用风险特征研究：行业变革中的主体类别差异
中国创新药企业在政策支持、人口老龄化需求及BD模式崛起下快速发展，2025年1－9月中国创新药交易总额达937亿美元，全球占比近半。未来，随着大型跨国药企进入专...
12-09 17:50
Kalaris Therapeutics Appoints Matthew Gall As New CFO To Support Growth And Clinical Expansion
Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew
11-03 20:38
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Vor Bio appoints Adi Osovsky, S.J.D., as General Counsel, bringing 17 years of legal expertise in biotechnology and pharmaceutical sectors. Osovsky previously served as Executive Vice President, Head of Legal & Corporate Secretary at iTeos Therapeutics, and held senior roles at Sarepta Therapeutics. Her experience includes governance, strategic transactions, and risk management. Osovsky holds degrees from Tel Aviv University and Harvard Law Schoo...
09-02 12:00
iTeos Therapeutics Completes Merger with Concentra Biosciences
The latest update is out from iTeos Therapeutics ( ($ITOS) ). On August 29, 202...
08-29 21:25
跨国药企洞察｜罗氏加码“减肥药物”500亿美元项目部分破土动工 多项早期管线“瘦身”
（来源：动脉新医药） 编者按： 全球视野下的跨国药企深度洞察——创新、博弈与中国答卷 在全球医药产业发展的宏大叙事中，跨国药企始终扮演着关键角色——他们...
08-27 18:33
GSK and iTeos Advance Immunotherapy Study for Lung Cancer
GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), Iteos Therapeut...
08-16 00:25
Wells Fargo Maintains Equal-Weight on ITeos Therapeutics, Lowers Price Target to $11
Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:ITOS) with a Equal-Weight and lowers the price target from $12 to $11.
08-07 22:48
ITeos Therapeutics Q2 EPS $(1.81) Misses $(0.95) Estimate
ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(0.95) by 89.73 percent. This is a 905.56 percent decrease over losses of $(0.18) per share
08-06 20:32
Concentra Biosciences To Acquire iTeos For $10.047 In Cash Per Share Plus One Non-Transferable Contingent Value Right
iTeos Therapeutics, Inc. ("iTeos") (NASDAQ:ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire iTeos for $10.047 in cash per share of
07-21 19:30
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
iTeos Therapeutics has entered into a definitive merger agreement with Concentra Biosciences, under which Concentra will acquire iTeos for $10.047 per share of common stock, plus a contingent value right (CVR). The iTeos board unanimously approved the agreement, deeming it in the best interest of all stockholders. The transaction will commence with a tender offer by August 1, 2025, subject to conditions including shareholder majority and $475 mil...
07-21 11:29
